CDK2 and cancer: Deficiency of BMI-1, an oncogenic cancer stem cell marker, has been shown to inhibit G1–S cell cycle transition through enhancement of p16Ink4a and p14Arf tumor-suppressor activities.24 Thus, concurrent silencing of CDK2 and BMI-1 by miR-302a may synergistically bring about G1/S cell cycle arrest of AGS cells.